Combined Androgen Blockade With Bicalutamide for Advanced Prostate Cancer.

The article presents a randomized controlled trial that compares the survival rate from combined androgen blockade (CAB) with bicalutamide versus lutenizing hormone-releasing hormone monotherapy for advanced prostate cancer. The results of the study demonstrated significant overall survival advantage in favor of CAB. It notes that the achievement of a prostate-specific antigen (PSA) nadir was a prognostic factor for cancer survival.